![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1566005
´Ü¹éÁú °áÇÕ ¾î¼¼ÀÌ ½ÃÀå : ¼¼°è ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м®, ±âȸ, ¿¹Ãø(2019-2030³â)Protein Binding Assays Market, By Technology; By Products & Services; By End User; By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa ), Global Trend Analysis, Competitive Landscape & Forecast, 2019-2030 |
¼¼°èÀÇ ´Ü¹éÁú °áÇÕ ¾î¼¼ÀÌ ½ÃÀåÀº CAGR ¾à10%·Î È®´ëÇϸç, 2030³â¿¡´Â 8¾ï 5,300¸¸ ´Þ·¯ Ãʰú
¼¼°èÀÇ ´Ü¹éÁú °áÇÕ ¾î¼¼ÀÌ ½ÃÀåÀº Drug Discovery¡¤¾àÁ¦ °³¹ß Ȱµ¿ÀÇ È°¹ßÈ, ¸¸¼ºÁúȯÀÇ Áõ°¡, Á¦¾à ¿¬±¸°³¹ß ÅõÀÚÀÇ È®´ë, °áÇÕ ±â¼ú¡¤¹æ¹ýÀÇ Áøº¸ µî¿¡ ÀÇÇØ ȣȲÀ» º¸À̰í ÀÖ½À´Ï´Ù.
Àü·« ÄÁ¼³ÆÃ ¹× ½ÃÀå Á¶»ç ±â°üÀÎ BlueWeave ConsultingÀº ÃÖ±Ù ¿¬±¸¿¡¼ 2023³â ¼¼°è ´Ü¹éÁú °áÇÕ ¾î¼¼ÀÌ ½ÃÀå ±Ô¸ð¸¦ 2024-2030³âÀÇ ¿¹Ãø ±â°£ Áß ±Ý¾× ±âÁØÀ¸·Î 4¾ï 4,452¸¸ ´Þ·¯·Î Ãß»êÇß½À´Ï´Ù, BlueWeave´Â ¼¼°è ´Ü¹éÁú °áÇÕ ¾î¼¼ÀÌ ½ÃÀå ±Ô¸ð°¡ ¿¬Æò±Õ 9.77% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 8¾ï 5,353¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ¼¼°èÀÇ ´Ü¹éÁú °áÇÕ ¾î¼¼ÀÌ ½ÃÀåÀº ½Å¾à °³¹ßÀÇ ¹ßÀü, ´Ü¹éÁú °£ »óÈ£ÀÛ¿ë¿¡ ´ëÇÑ ÀÌÇØÀÇ ½ÉÈ, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇÏÀ̽º·çDz ½ºÅ©¸®´× ¹× Çü±¤ ±â¹Ý ºÐ¼®ÀÇ ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ ÀÌ·¯ÇÑ ºÐ¼®ÀÇ È¿À²¼º°ú Á¤È®¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. Á¦¾à ¹× »ý¸í°øÇÐ »ê¾÷ÀÇ ºÎ»ó°ú ÀǾàǰ °³¹ß¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ³ë·ÂÀº ¼¼°èÀÇ ´Ü¹éÁú °áÇÕ ¾î¼¼ÀÌ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
±âȸ - µ¿¹ÝÀÚ Áø´ÜÀ¸·Î È®Àå
µ¿¹ÝÀÚ Áø´ÜÀÇ Ã¤Åà Ȯ´ë´Â ºÐ¼® ±â°£ Áß ¿¬Æò±Õ ¼ºÀå·ü(CAGR)·Î ¼¼°è ´Ü¹éÁú °áÇÕ ¾î¼¼ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸ÂÃãÇü ÀÇ·á°¡ ÃßÁø·ÂÀ» ¾òÀ½¿¡ µû¶ó ƯÁ¤ Ä¡·á¿¡ ´ëÇÑ È¯ÀÚÀÇ ¹ÝÀÀÀ» ¿¹ÃøÇϱâ À§ÇØ µ¿¹Ý Áø´ÜÀÌ Á¡Á¡ ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ È®Àå¿¡´Â ¾à¹°ÀÇ È¿´É°ú ¾ÈÀü¼ºÀ» °áÁ¤ÇÏ´Â µ¥ Áß¿äÇÑ ¾à¹°-´Ü¹éÁú »óÈ£ÀÛ¿ëÀ» Æò°¡Çϱâ À§ÇÑ Á¤È®ÇÑ ´Ü¹éÁú °áÇÕ ¾î¼¼ÀÌÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®¹ýÀ» µ¿¹ÝÁø´Ü¿¡ ÅëÇÕÇÏ´Â °ÍÀº ÀǾàǰ °³¹ßÀÇ °ü·Ã¼ºÀ» ³ôÀÌ°í ½ÃÀå °³Ã´ÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.
ÁöÁ¤ÇÐÀû ±äÀå Áõ°¡°¡ ¼¼°è ´Ü¹éÁú °áÇÕ ¾î¼¼ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâ
ÁöÁ¤ÇÐÀû ±äÀåÀÌ °íÁ¶µÇ¸é °ø±Þ¸Á¿¡ ¿µÇâÀ» ¹ÌÃÄ ¿øÀÚÀç ºñ¿ëÀ» »ó½Â½ÃŰ°í »ý»ê ¹× À¯ÅëÀ» Áö¿¬½ÃÅ´À¸·Î½á ¼¼°è ´Ü¹éÁú °áÇÕ ¾î¼¼ÀÌ ½ÃÀåÀ» È¥¶õ¿¡ ºü¶ß¸± ¼ö ÀÖ½À´Ï´Ù. ¹«¿ª Á¦ÇÑ ¹× Á¦Àç Á¶Ä¡·Î ÀÎÇØ ÇÙ½É ¼ººÐ¿¡ ´ëÇÑ Á¢±ÙÀÌ Á¦ÇÑµÉ ¼ö ÀÖÀ¸¸ç, ½ÃÀåÀÇ ºÒÈ®½Ç¼ºÀ¸·Î ÀÎÇØ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ°¡ °¨¼ÒÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁöÁ¤ÇÐÀû ºÒ¾ÈÁ¤¼ºÀ¸·Î ÀÎÇØ ±¹³» Á¶´Þ·Î ½ÃÀå Áß½ÉÀÌ À̵¿ÇÏ¿© Áö¿ª ½ÃÀå ¿ªÇп¡ ¿µÇâÀ» ¹ÌÄ¡°í ¾÷°èÀÇ ½Å±â¼ú äÅÃÀÌ Áö¿¬µÉ ¼ö ÀÖ½À´Ï´Ù.
ÃÖÁ¾»ç¿ëÀÚº°·Î´Â ¹ÙÀÌ¿À Á¦¾à»ç°¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
¼¼°è ´Ü¹éÁú °áÇÕ ¾î¼¼ÀÌ ½ÃÀå¿¡¼ Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ÀÌ °¡Àå Å« ÃÖÁ¾»ç¿ëÀÚÀÔ´Ï´Ù. ´Ü¹éÁú °áÇÕ ÃøÁ¤ÀÌ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â ½Å¾à °³¹ß ¹× ½ÃÀå °³¹ß ÇÁ·Î¼¼½º¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä·Î ÀÎÇØ ¹ÙÀÌ¿À Á¦¾à ȸ»ç°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í Àü ¼¼°è¿¡¼ Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ ºÐ¾ß ½ÃÀå Áö¹è·Â¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¼¼°èÀÇ ´Ü¹éÁú °áÇÕ ¾î¼¼ÀÌ ½ÃÀå¿¡¼ ´Ù¸¥ ÁÖ¿ä ÃÖÁ¾»ç¿ëÀڷδ CRO ¹× ÄÁ¼³ÆÃ ȸ»ç°¡ ÀÖ½À´Ï´Ù.
°æÀï ±¸µµ
¼¼°èÀÇ ´Ü¹éÁú °áÇÕ ¾î¼¼ÀÌ ½ÃÀåÀº Ä¡¿ÇÑ °æÀïÀÌ µµÀԵǰí ÀÖÀ¸¸ç, ¼ö¸¹Àº ±â¾÷ÀÌ ½ÃÀå Á¡À¯À² È®´ë¸¦ À§ÇØ °æÀïÇϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷¿¡´Â Thermo Fisher Scientific, Inc., Charles River, Sovicell GMBH, XenoTech, GE Healthcare, Eurofins Scientific, Creative Biolabs, Evotec(Cyprotex), Bioduro, BioAgilytix Labs, WuXi AppTec, Domainex µîÀÌ ÀÖ½À´Ï´Ù. ÀÌµé ±â¾÷Àº R&D ÅõÀÚ È®´ë, ÀμöÇÕº´, ÇÕÀÛÅõÀÚ, Á¦ÈÞ, ¶óÀ̼±½Ì °è¾à, ½ÅÁ¦Ç° ¹× ¼ºñ½º Ãâ½Ã µî ´Ù¾çÇÑ Àü·«À» ÅëÇØ ¼¼°è ´Ü¹éÁú °áÇÕ ¾î¼¼ÀÌ ½ÃÀå¿¡¼ÀÇ ÀÔÁö¸¦ ´õ¿í °ÈÇϰí ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼´Â ¼¼°è ´Ü¹éÁú °áÇÕ ¾î¼¼ÀÌ ½ÃÀåÀÇ ¼ºÀå ÀáÀç·Â, ÇâÈÄ µ¿Çâ ¹× Åë°è¿¡ ´ëÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ Àüü ½ÃÀå ±Ô¸ð ¿¹ÃøÀ» ÃËÁøÇÏ´Â ¿äÀο¡ ÁÖ¸ñÇϰí ÀÖ½À´Ï´Ù. ÀÌ º¸°í¼´Â ¼¼°è ´Ü¹éÁú °áÇÕ ¾î¼¼ÀÌ ½ÃÀåÀÇ Ãֽбâ¼ú µ¿Çâ°ú ÀÇ»ç°áÁ¤ÀÚ°¡ ¿Ã¹Ù¸¥ Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ´Â ¾÷°è ÀλçÀÌÆ®À» Á¦°øÇϱâ À§ÇØ ÃÖ¼±À» ´ÙÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, µµÀü °úÁ¦, °æÀï·Â¿¡ ´ëÇØ¼µµ ºÐ¼®ÇÕ´Ï´Ù.
Global Protein Binding Assays Market Expands at CAGR of almost 10% to Surpass Value of USD 853 Million by 2030
Global Protein Binding Assays Market is thriving due to rising drug discovery and development activities, increasing prevalence of chronic diseases, growing pharmaceutical R&D investments, and advancements in binding technologies and techniques.
BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global Protein Binding Assays Market size by value at USD 444.52 million in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global Protein Binding Assays Market size to expand at a CAGR of 9.77% reaching a value of USD 853.53 million in 2030. Global Protein Binding Assays Market is driven by several key factors including advancements in drug discovery, a growing understanding of protein-protein interactions, and the increasing demand for personalized medicine. Additionally, technological advancements in high-throughput screening and fluorescence-based assays enhance the efficiency and accuracy of these assays. The rising pharmaceutical and biotechnology industries, along with continuous efforts in drug development, further propel the growth of Global Protein Binding Assays Market.
Opportunity - Expansion into Companion Diagnostics
The growing adoption of companion diagnostics is expected to boost the growth of Global Protein Binding Assays Market at a significant CAGR during the period in analysis. As personalized medicine gains momentum, companion diagnostics are increasingly used to predict patient response to specific therapies. The expansion requires accurate protein binding assays to assess drug-protein interactions, which are critical in determining drug efficacy and safety. The integration of these assays into companion diagnostics enhances their relevance in drug development, driving market growth.
Impact of Escalating Geopolitical Tensions on Global Protein Binding Assays Market
Escalating geopolitical tensions can disrupt the Global Protein Binding Assays Market by affecting supply chains, increasing costs of raw materials, and causing delays in production and distribution. Trade restrictions and sanctions may limit access to critical components, while market uncertainty could lead to reduced investment in research and development. Additionally, geopolitical instability may shift market focus toward domestic sourcing, influencing regional market dynamics and potentially slowing the adoption of new technologies in the industry.
Biopharma Companies Hold Largest Share in Market by End User
The pharmaceutical and biotechnology companies segment is the largest end user segment in Global Protein Binding Assays Market. Biopharma companies dominate the market due to the high demand for drug discovery and development processes, where protein binding assays play a critical role. The increasing focus on personalized medicine and the growing number of pharmaceutical and biotech firms globally contribute significantly to the segment's dominance in the market. The other major end user segments in Global Protein Binding Assays Market include CROs and consulting firms.
Competitive Landscape
Global Protein Binding Assays Market is fiercely competitive, with numerous companies vying for a larger market share. Major companies in the market include Thermo Fisher Scientific, Inc., Charles River, Sovicell GMBH, XenoTech, GE Healthcare, Eurofins Scientific, Creative Biolabs, Evotec (Cyprotex), Bioduro, BioAgilytix Labs, WuXi AppTec, and Domainex. These companies use various strategies, including increasing investments in their R&D activities, mergers and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in Global Protein Binding Assays Market.
The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Protein Binding Assays Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Protein Binding Assays Market and industry insights to help decision-makers make sound strategic decisions. Further, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.
*Financial information of non-listed companies can be provided as per availability.
**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable